PER
Director Trades
| Date | Director | Value |
|---|---|---|
| 13/11/24 | J. Garner | $30,000 |
| 26/11/24 | J. Garner | $8,938 |
| 23/12/24 | J. Garner | $10,500 |
| 30/12/24 | C. Gittleson | $15,000 |
| 25/2/25 | J. Garner | $475,277 |
| 27/3/25 | J. Garner | $81,871 |
| 30/3/25 | B. Price | $58,121 |
| 29/6/25 | J. Garner | $24,960 |
Company News
Percheron Therapeutics acquires worldwide licence to commercialise HMBD-002 cancer therapy
Percheron Therapeutics (ASX: PER) has acquired a worldwide exclusive license from Singapore-based Hummingbird Bioscience for monoclonal antibody therapy HMBD-002 to treat a range of cancer indications. The company will pay Hummingbird an upfront consideration of $4.6 million plus milestone payments of as much as $443m and royalties on net sales of the commercial product. Percheron […]
Percheron Therapeutics completes toxicology study for avicursen ahead of US FDA discussions
Australian biotechnology company Percheron Therapeutics (ASX: PER) has completed a nine-month toxicology study in non-human primates for its lead program, avicursen. Avicursen is an antisense oligonucleotide that targets the CD49d biomarker. The study, which commenced in March 2023, concluded its final dosing on schedule in December. Recovery phase The majority of subjects in the study […]